http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김영은,Un Ho Jung,Dahye Song,임효빈,Tae Ho Lee,Dong Hyun Chun,Min Hye Youn,이기봉,구기영 한국공업화학회 2023 Journal of Industrial and Engineering Chemistry Vol.119 No.-
To produce high-purity 1-octene, the dehydration of 1-octanol was performed over a dual-bed catalyticsystem comprising Al2O3 and Ba/Al2O3 catalysts. The influence of the catalyst weight on the activities ofAl2O3 and Ba/Al2O3 single-bed systems was initially investigated at liquid hourly space velocities (LHSVs)of 7–168 h1 at 400 C. For the Al2O3 single-bed system, the 1-octene selectivity decreased with anincrease in the catalyst weight. Although the 1-octene selectivity of Ba/Al2O3 increased owing to theanti-Saytzeff effect, its yield was limited due to a low 1-octanol conversion. The efficiency of the dualbedcatalytic system was subsequently investigated by varying the catalyst bed ratio (i.e., xAl–yBa). The 40Al-60Ba catalytic system afforded a higher conversion (95.3%) and productivity than the Ba/Al2O3 single-bed system at an LHSV of 56 h1. Moreover, the 10Al-90Ba catalytic system with a highBa/Al2O3 catalyst ratio exhibited a high 1-octene productivity at LHSVs of 7–28 h1, while also yieldinga high-purity product. The single-bed system exhibited a lower selectivity toward 1-octene than thedual-bed system, and after 100 h, the 10Al-90Ba dual-bed system offered a stable catalytic performanceregardless of the small reductions in the 1-octene selectivity and yield.
Jin Hong-Guang,Kim Kwan-Woo,Li Jing,Lee Dae Young,Yoon Dahye,Jeong Jin Tae,Kim Geum-Soog,Oh Hyuncheol,An Ren-Bo,Kim Youn-Chul 한국응용생명화학회 2022 Applied Biological Chemistry (Appl Biol Chem) Vol.65 No.1
The phytochemical investigation on the methanol extract of the rhizomes of Atractylodes macrocephala resulted in the discovery of one new compound 9α-hydroxyatractylenolide (1) and 21 known compounds including atractylone (2), 3β-acetoxyatractylon (3), atractylenolide I (4), atractylenolide II (5), 8-epiasterolid (6), atractylenolide III (7), atractylenolide VII (8), 8-epiatractylenolide III (9), eudesm-4(15)-ene-7α,11-diol (10), linoleic acid (11), myristic acid (12), 3-O-caffeoyl-1-methyquinic acid (13), (2E,8E,10E)-tetradecatriene-4,6-diyne-1,14-diol (14), 14-aceroxy-12-senecioyloxytetradeca- 2E,8Z,10E-trien-4,6-diyn-1-ol (15), isoscopoletin (16), caffeic acid (17), protocatechic acid (18), 3-O-caffeoylquinic acid (19), 4-O-caffeoylquinic acid (20), 1,5-di-O-caffeoylquinic acid (21), and nicotinic acid (22). Their structures were identified using nuclear magnetic resonance (NMR) and mass spectroscopy, and by comparison with previously published data. Compounds 4, 5, 6, 8, and 10–22 significantly inhibited lipopolysaccharide (LPS)- induced nitric oxide (NO) production in RAW264.7 macrophages, and compounds 4, 5, 6, 16, and 17 showed those responses in BV2 microglial cells. Especially, compound 6 showed the second-best effect, and inhibited the LPSinduced production of prostaglandin E2 ( PGE2), the protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2, and the production of cytokines including interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α in both cells. These inhibitory effects were mediated by the inactivation of nuclear factor kappa B (NF-κB) signaling pathway.
Kyung-Ah Kim,Gwang Hyun Choi,Eun Sun Jang,Young Seok Kim,Youn Jae Lee,In Hee Kim,Sung Bum Cho,Moran Ki,Hwa Young Choi,Dahye Paik,Sook-Hyang Jeong 한국역학회 2021 Epidemiology and Health Vol.43 No.-
OBJECTIVES: Injection drug use is a major risk factor for hepatitis C virus (HCV) infection; however, limited data on this topic are available in Korea. Thus, this study aimed to investigate the epidemiological and clinical characteristics, treatment uptake, and outcomes of HCV infection among people who inject drugs (PWID). METHODS: We used the data from the Korea HCV cohort, which prospectively enrolled patients with HCV infection between 2007 and 2019. Clinical data and results of a questionnaire survey on lifetime risk factors for HCV infection were analyzed according to a self-reported history of injection drug use (PWID vs. non-PWID group). RESULTS: Among the 2,468 patients, 166 (6.7%) were in the PWID group, which contained younger patients (50.6±8.2 vs. 58.2±13.1 years) and a higher proportion of male (81.9 vs. 48.8%) than the non-PWID group. The distribution of PWID showed significant regional variations. Exposure to other risk factors for HCV infection was different between the groups. The proportion of patients with genotype non-2 infection was higher in the PWID group. Treatment uptake was higher in the PWID group in the interferon era; however, it was comparable between the groups in the direct-acting antiviral era. The rate of sustained virological response did not significantly differ between the groups. CONCLUSIONS: As of 2019, PWID constituted a minority of HCV-infected people in Korea. The epidemiological characteristics, but not treatment uptake and outcomes, were different between the PWID and non-PWID groups. Therefore, active HCV screening and treatment should be offered to PWID in Korea.
( Gwang Hyeon Choi ),( Eun Sun Jang ),( Young Seok Kim ),( Youn Jae Lee ),( In Hee Kim ),( Sung Bum Cho ),( Han Chu Lee ),( Jang Jeong Won ),( Moran Ki ),( Hwa Young Choi ),( Dahye Baik ),( Sook-hyang 대한간학회 2020 춘·추계 학술대회 (KASL) Vol.2020 No.1
Aims: This study aimed to elucidate the all-cause mortality and the incidence hepatocellular carcinoma (HCC), and their related factors among the patients with chronic hepatitis C virus (HCV) infection in South Korea. Methods: A total 2,369 patients with HCV RNA positivity and no HCC at diagnosis (mean age 57.5 years, 47.6% male, 29.8% cirrhosis) were prospectively enrolled in 6 university hospitals from May 2007 to March 2019 and followed until February 2020. The patients were classified into untreated group (n=753, 31.8%), interferon (IFN)-based treated group (n=698, 29.5%), and direct-acting antivirals (DAA)-treated group (n=918, 38.8%). Kaplan-Meier curve analysis and Cox regression analysis were performed. Results: During 4.3 years (IQR 2.5-7.6) of median follow-up, 245 patients died and 147 developed HCC. The 3-, 5-, and 10-year cumulative mortality in the HCV patients was 4.6%, 8.0%, and 12.8%, respectively. The 3-, 5-, and 10-year cumulative incidence of HCC was 4.5%, 8.5%, and 18.3%, respectively. The SVR rate was 68.7% in IFN-based treated group and 95.2% in DAA-treated group, by per-protocol analysis. After multivariate analysis, achievement of SVR was an independent factor for decreased risk of HCC (adjusted hazard ratio [aHR] 0.22, 95% confidence interval [CI] 0.12-0.39, P<0.001 for IFN based-treated group and aHR 0.29, 95% CI 0.17-0.50, P<0.001 for DAA-treated group, respectively). SVR was an independent factor for decreased risk of all cause of mortality (aHR 0.27, 95% CI 0.17-0.44, P<0.001 for IFN based-treated group and aHR 0.23, 95% CI 0.12-0.45, P<0.001 for DAA-treated group, respectively) along with other factors. Conclusions: In Korea HCV cohort, 5-year cumulative incidence of HCC and mortality was 8.0% and 8.5%, respectively. The overall treatment rate was 70% with overall SVR rate of 86%. Achievement of SVR was a strong factor for better outcomes, which support active screening and treatment of HCV infection.